Nervous System News and Research

Latest Nervous System News and Research

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

German Research Foundation to establish new CRC at Mainz University Medical Center

On January 1, 2013, the German Research Foundation (DFG) will establish a new Collaborative Research Center (CRC) at the University Medical Center of Johannes Gutenberg University Mainz (JGU).

30 Nov 2012

ArmaGen closes $17M Series A financing

ArmaGen Technologies, Inc. today announced the closing of a $17 million Series A financing to support the development of brain-penetrating recombinant protein therapeutics.

29 Nov 2012

Yale and Mainz University Medical Center to extend collaboration

The University Medical Center at Johannes Gutenberg University Mainz, Germany and the renowned School of Medicine at Yale University, USA have agreed upon a future collaboration. This strategic partnership promises to provide an innovative stimulus for the Research Unit Translational Neurosciences at the Mainz University Medical Center. The resulting regular exchange will benefit both basic research and the training of young researchers.

29 Nov 2012

Suvorexant may bring help for people with insomnia

A new drug may bring help for people with insomnia, according to a study published in the November 28, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

29 Nov 2012

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring key sets of VIMPAT® (lacosamide) C-V data at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, Calif., November 30 - December 4.

29 Nov 2012

Pfizer completes acquisition of NextWave Pharmaceuticals

Pfizer Inc. today announced that it has completed its acquisition of NextWave Pharmaceuticals, Inc., a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).

29 Nov 2012

High-resolution real-time images show how nerves may be damaged during earliest stages of MS

High-resolution real-time images show in mice how nerves may be damaged during the earliest stages of multiple sclerosis. The results suggest that the critical step happens when fibrinogen, a blood-clotting protein, leaks into the central nervous system and activates immune cells called microglia.

28 Nov 2012

Specific combination of two pharmaceutical substances show promise against multiple sclerosis

A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects. To achieve this, a team of scientists under the leadership of Prof. Gunter Fischer and Dr. Frank Striggow have combined two already approved pharmaceutical substances with each other using a chemical linker structure.

27 Nov 2012

New way to protect neurons that express mutant huntingtin proteins

By using a model, researchers at the University of Montreal have identified and "switched off" a chemical chain that causes neurodegenerative diseases such as Huntington's disease, amyotrophic lateral sclerosis and dementia. The findings could one day be of particular therapeutic benefit to Huntington's disease patients. "We've identified a new way to protect neurons that express mutant huntingtin proteins," explained Dr. Alex Parker of the University of Montreal's Department of Pathology and Cell Biology and its affiliated CRCHUM Research Centre.

27 Nov 2012

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Seattle Genetics, Inc. announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL).

26 Nov 2012

Weight loss and quality of sleep: an interview with Kerry Stewart

In our particular study we used a survey which consisted of 50 different questions which get at different aspects of sleep health. It was a patient self-report.

26 Nov 2012

Study confirms high biocompatibility of polymeric materials with brain tissue

Professor José Miguel Soria, a member of the Institute of Biomedical Sciences, Universidad CEU Cardenal Herrera, has co-directed with Professor Manuel Monleón of the Universitat Politècnica de València a study on the compatibility of polymeric biomaterials in the brain and its effectiveness to favour neuroregeneration in areas with some kind of damage or brain injury.

26 Nov 2012

Apitope announces completion of recruitment in ATX-MS-1467 Phase I trial for MS

Apitope, the European drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion of recruitment into its second Phase I clinical trial of ATX-MS-1467 in patients with multiple sclerosis (MS).

26 Nov 2012

People with Parkinson's benefit from exercise programs on stationary bicycles

People with Parkinson's disease benefit from exercise programs on stationary bicycles, with the greatest effect for those who pedal faster, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

26 Nov 2012

Alcohol exposure during fetal development alters brain structure and metabolism in children

Children exposed to alcohol during fetal development exhibit changes in brain structure and metabolism that are visible using various imaging techniques, according to a new study being presented today at the annual meeting of the Radiological Society of North America (RSNA).

26 Nov 2012